‘Pull Every Lever’: FDA’s Marks Worries Gene Therapies Could Falter Without Help To Lower Cost

 
• By Derrick Gingery

CBER’s director says manufacturing and regulatory issues need to be resolved to ensure the gene therapy sector thrives.

clean room
The FDA wants to help reduce the cost of gene therapy manufacturing, such as labor-intensive clean room work. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies